^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

Progesterone receptor agonist

4d
New trial
|
megestrol • TheraCIM (nimotuzumab)
4d
New trial
|
megestrol
4d
Ovulation induction with oral contraception alone in biochemical to overt primary ovarian insufficiency: a pilot study. (ChiCTR2500111618)
P=N/A, N=32, Not yet recruiting, Xiangya Hospital, Central South University; Xiangya Hospital, Central South University
New trial
4d
A study on the correlation of drug metabolism and human body composition based on the bioequivalence trial of Progesterone Sustained-release vaginal gel (ChiCTR2500115150)
P=N/A, N=48, Completed, The Second Affiliated Hospital of Wenzhou Medical University; The Second Affiliated Hospital of Wenzhou Medical University
New trial
5d
The role of PAQR3 in cancer progression - Molecular regulation, signaling pathways, and clinical implications: A review. (PubMed, Biomol Biomed)
Progesterone and adiponectin receptor 3 (PAQR3) is a Golgi-localized seven-transmembrane protein that anchors rapidly accelerated fibrosarcoma kinase (Raf) and suppresses rat sarcoma/rapidly accelerated fibrosarcoma/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (Ras/Raf/MEK/ERK) signaling, thereby influencing cellular proliferation, differentiation, and metastasis...These effects are modulated by upstream regulators, including microRNA-543 (miR-543), circular RNA 0043280/microRNA-203a-3p (circ_0043280/miR-203a-3p), microRNA-15b (miR-15b), human epidermal growth factor receptor 2 (HER2), 5-aza-2'-deoxycytidine (5-Aza-CdR), autophagy-related 7 (ATG7), and damage-specific DNA binding protein 2 (DDB2). In conclusion, PAQR3 functions as a tumor suppressor and holds potential as a prognostic biomarker. Targeting PAQR3-related pathways may provide new therapeutic opportunities.
Review • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • MIR543 (MicroRNA 543) • DDB2 (Damage Specific DNA Binding Protein 2) • ATG7 (Autophagy Related 7) • MIR15B (MicroRNA 15b) • MIR203A (MicroRNA 203a)
9d
Analysis of the Relationship Between Early Estrogen Response and Cryptorchidism. (PubMed, Endocr Metab Immune Disord Drug Targets)
This study provided translational insights, enhancing the current understanding of testicular pathogenesis and contributing to the diagnosis and treatment of cryptorchidism.
Journal
|
SPI1 (Spi-1 Proto-Oncogene)
11d
Sex hormones and tuberculosis: Implications for immune regulation, susceptibility, and disease pathogenesis. (PubMed, Tuberculosis (Edinb))
Increasing evidence indicates that sex steroid hormones estrogen, progesterone, and testosterone modulate immune responses critical for MTB control...However, circulating hormone data in TB patients are inconsistent, highlighting the need for longitudinal, hormone-aware studies. Overall, sex hormone mediated immune modulation influences TB susceptibility and pathogenesis, and future research should adopt sex and hormone-dose-aware designs to optimize host-directed therapies.
Review • Journal
|
IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • IL1B (Interleukin 1, beta) • IL4 (Interleukin 4) • IL5 (Interleukin 5)
12d
Case Report: Pembrolizumab associated lichen planus in early stage triple negative breast cancer. (PubMed, Front Oncol)
Triple negative breast cancer (TNBC) is a breast cancer with a poor prognosis, marked by the absence of estrogen (ER) and progesterone (PR) receptors as well as human epidermal growth factor receptor (HER2) expression. Several skin-related side effects have been documented, such as pruritus, maculopapular rashes, vitiligo, lichenoid skin reactions, psoriasis, and, in rare cases, severe and potentially life-threatening conditions. We report a rare case of pembrolizumab-associated lichen planus in a 43-year-old woman who received pembrolizumab for neoadjuvant treatment of TNBC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PD-L2 (Programmed Cell Death 1 Ligand 2)
|
HER-2 expression
|
Keytruda (pembrolizumab)
13d
Nanocrystalline Megestrol Acetate for Cachectic Stage Locally Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
P3, N=68, Not yet recruiting, Changchun GeneScience Pharmaceutical Co., Ltd.
New P3 trial
|
megestrol
13d
Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer (clinicaltrials.gov)
P2, N=51, Active, not recruiting, Northwestern University | Trial primary completion date: Dec 2025 --> Aug 2025
Trial primary completion date
|
megestrol